Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery.

Duleek Ranatunga

Pear Bio

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery.

Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who don't respond to available treatments.

The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. 

Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who don't respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.


SOSV

RebelBio

Greater London Authority

Hoxton Ventures

Fly Ventures

Wavemaker 360

Octopus Ventures

Compound

Crista Galli Ventures

Our Winter 2023 newsletter now out, with a focus on our clinical trial work

https://lnkd.in/ewiz_XVw

Let us know if you have questions, or want to know more about our clinical trials!

The Pear Bio team is excited to have set up our first US lab in the Boston area at ABI-LAB 2 this month! The facilities and support provided by the team are second to none 🇺🇸  🇺🇸  🇺🇸 

This lab will focus on US clinical trials & lab developed testing.

We are looking forward to this new chapter for the company!

Really delighted that we have support from a range of charities for our trials.

Pear-Tree2 in kidney cancer from Kidney Cancer UK
Pear-TNBC in Triple Negative Breast Cancer from Breast Cancer Now

and both are open across a range of hospitals

https://lnkd.in/d5iYhvgV
https://lnkd.in/dYrU_EiZ

To read more about our trials, see here: https://lnkd.in/dvJkA5CN

Metric
Company Name	Pear Bio
Symbol
MSH ID	COM:PEARBIO
Market	PRIVATE
Sector	Healthcare
Industry	Biotechnology Research
Country	GB
Stage
Employee Count	34
Website	pearbio.com
LinkedIn	pear-bio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:PEARBIO

Pear Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue